Today’s Rating On Watch: Maxim Group Reiterates $18 PT On Cellular Biomedicine (OTC:CBMG), Reiterates Buy Rating

November 29, 2016 - By Peter Kolinski

Today's Rating On Watch: Maxim Group Reiterates $18 PT On Cellular Biomedicine (OTC:CBMG), Reiterates Buy Rating

Cellular Biomedicine (OTC:CBMG) Rating

In analysts report issued to investors and clients on Tuesday morning, Cellular Biomedicine (OTC:CBMG) stock Buy was restate by Analysts at Maxim Group. They currently have a $18 TP on the stock. Maxim Group’s TP suggests a potential upside of 29.50% from the company’s last close price.

About 27,760 shares traded hands or 31.50% up from the average. Cellular Biomedicine Group Inc (OTC:CBMG) has declined 21.37% since April 26, 2016 and is downtrending. It has underperformed by 26.63% the S&P500.

Analysts await Cellular Biomedicine Group Inc (NASDAQ:CBMG) to report earnings on March, 13.

Insitutional Activity: The institutional sentiment decreased to 2 in 2016 Q2. Its down 2.17, from 4.17 in 2016Q1. The ratio dived, as 2 funds sold all Cellular Biomedicine Group Inc shares owned while 4 reduced positions. 6 funds bought stakes while 19 increased positions. They now own 2.46 million shares or 131.54% more from 1.06 million shares in 2016Q1.

Credit Suisse Ag last reported 0% of its portfolio in the stock. Tower Research Capital Limited Liability Com (Trc) holds 0% or 868 shares in its portfolio. Creative Planning holds 0% of its portfolio in Cellular Biomedicine Group Inc (NASDAQ:CBMG) for 300 shares. California Pub Employees Retirement has invested 0% of its portfolio in Cellular Biomedicine Group Inc (NASDAQ:CBMG). Blackrock Advsr Limited Company reported 5,513 shares or 0% of all its holdings. National Bank Of America De accumulated 329 shares or 0% of the stock. New York State Common Retirement Fund has invested 0% of its portfolio in Cellular Biomedicine Group Inc (NASDAQ:CBMG). Geode Mngmt Ltd Limited Liability Company has 0% invested in the company for 55,422 shares. Blackrock Mgmt Ltd Liability Company holds 0% of its portfolio in Cellular Biomedicine Group Inc (NASDAQ:CBMG) for 46,413 shares. Moreover, Deutsche Commercial Bank Ag has 0% invested in Cellular Biomedicine Group Inc (NASDAQ:CBMG) for 1,950 shares. Citigroup reported 1,220 shares or 0% of all its holdings. Morgan Stanley accumulated 50 shares or 0% of the stock. State Street Corp reported 114,909 shares or 0% of all its holdings. Moreover, Nationwide Fund Advsrs has 0% invested in Cellular Biomedicine Group Inc (NASDAQ:CBMG) for 7,243 shares. Goldman Sachs Incorporated, a New York-based fund reported 18,703 shares.

Cellular Biomedicine Group, Inc. is a biomedicine company. The company has a market cap of $199.50 million. The Firm is engaged in the development of treatments for cancerous and degenerative diseases utilizing cell technologies. It currently has negative earnings. The Firm operates in Biomedicine Cell Therapy segment.

According to Zacks Investment Research, “Cellular Biomedicine Group Inc. is a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases utilizing proprietary cell therapy technologies. The Company offers developmental stem cell, progenitor cell, and immune cell projects. It is developing treatments utilizing proprietary cell technologies for the treatment of a range of cancers; joint disease and central nervous system diseases. Cellular Biomedicine Group Inc. is headquartered in Palo Alto, California.”

CBMG Company Profile

Cellular Biomedicine Group, Inc. (CBMG), incorporated on January 18, 2013, is a biomedicine company. The Firm is engaged in the development of treatments for cancerous and degenerative diseases utilizing cell technologies. The Firm operates in Biomedicine Cell Therapy segment. The Company’s technology includes platforms, such as Immune Cell therapy for treatment of broad range of cancers using Vaccine, T Cells Receptor (TCR) clonality analysis technology and T Central Memory Cell (Tcm) preparation methodologies, Chimeric Antigen Receptor T cell (CAR-T), and human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases, with primary research and manufacturing facilities in China. The Firm is focused on developing and marketing cell therapies based on its cellular platforms, to treat serious chronic and degenerative diseases, such as cancer, orthopedic diseases, including osteoarthritis and tissue damage, various inflammatory diseases and metabolic diseases.

More news for Cellular Biomedicine Group Inc (NASDAQ:CBMG) were recently published by: Streetinsider.com, which released: “Cellular Biomedicine Group (CBMG) Approved in China to Commence CAR-T Against …” on November 29, 2016. Globenewswire.com‘s article titled: “Cellular Biomedicine Group Announces Dismissal of Class Action Litigation” and published on August 18, 2016 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>